Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Yamada, Yuichiro; Katagiri, Hideki; Hamamoto, Yoshiyuki; Deenadayalan, Srikanth; Navarria, Andrea; Nishijima, Keiji; Seino, Yutaka; Fukushima, Y; Hamamoto, Y; Hisatomi, A; Ide, Y; Inoue, S; Kawada, T; Kim, H; Kiyosue, A; Matoba, K; Matsuoka, O; Nishimura, H; Noguchi, M; Osonoi, T; Sawada, S; Shibasaki, Y; Shin, K; Yamada, Y

doi:10.1016/s2213-8587(20)30075-9

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

BACKGROUND Given the unique phenotype of type 2 diabetes in Japanese patients, novel therapies such as oral semaglutide require evaluation in this population. PIONEER 9 aimed to assess the dose-response of oral semaglutide and to compare the efficacy and safety of oral semaglutide with placebo an…